Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,662 as of Friday, May 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,201 issues advancing vs. 1,742 declining with 169 unchanged.

The Health Services industry currently sits down 0.4% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Abbott Laboratories ( ABT), up 0.8%, and Edwards Lifesciences ( EW), up 0.7%. On the negative front, top decliners within the industry include Intuitive Surgical ( ISRG), down 1.7%, Agilent Technologies ( A), down 1.1%, Catamaran ( CTRX), down 1.0%, Humana ( HUM), down 0.7% and Boston Scientific ( BSX), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Services industry higher today. As of noon trading, DaVita HealthCare Partners is up $0.50 (0.7%) to $70.40 on light volume. Thus far, 357,953 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $69.87-$70.68 after having opened the day at $69.88 as compared to the previous trading day's close of $69.90.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. DaVita HealthCare Partners has a market cap of $14.8 billion and is part of the health care sector. Shares are up 10.3% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, notable return on equity and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Becton Dickinson ( BDX) is up $0.73 (0.6%) to $117.73 on light volume. Thus far, 187,987 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 806,500 shares. The stock has ranged in price between $116.77-$117.91 after having opened the day at $116.94 as compared to the previous trading day's close of $117.00.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $22.6 billion and is part of the health care sector. Shares are up 5.9% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts who rate Becton Dickinson a buy, 2 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, good cash flow from operations and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Becton Dickinson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Covidien ( COV) is up $0.42 (0.6%) to $73.04 on light volume. Thus far, 391,208 shares of Covidien exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $72.62-$73.16 after having opened the day at $72.62 as compared to the previous trading day's close of $72.62.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $32.8 billion and is part of the health care sector. Shares are up 6.6% year-to-date as of the close of trading on Thursday. Currently there are 15 analysts who rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, notable return on equity and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Covidien Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null